Pulmonary hypertension in critical care

Area of Science:

• Critical Care Medicine
• Cardiology
• Pulmonology

Background:

• Pulmonary hypertension (PH) is defined as mean pulmonary artery pressure (mPAP) ≥ 25 mmHg at rest.
• Recent updates in PH classification (2009) aid critical care management.
• Intensive care unit (ICU) management of PH relies on expert opinion.

Purpose of the Study:

• To review contemporary management strategies for patients with pulmonary hypertension in critical care settings.
• To highlight recent advancements in diagnostics and therapeutics for PH in the ICU.

Main Methods:

• Review of current literature and expert opinion on PH management in critical care.
• Discussion of diagnostic tools including echocardiography and pulmonary artery catheterization.
• Evaluation of emerging pharmacotherapies such as calcium sensitizers and phosphodiesterase type 5 inhibitors.

Main Results:

• Echocardiography offers noninvasive PH assessment; pulmonary artery catheterization is reserved for complex cases.
• Calcium sensitizers demonstrate inotropic effects and vasodilation, beneficial for right ventricular failure (RVF), especially in acute respiratory distress syndrome (ARDS).
• Phosphodiesterase type 5 (PDE5) inhibitors enhance response to inhaled nitric oxide and mitigate rebound vasoconstriction.

Conclusions:

• Contemporary management of PH in critical care integrates updated classifications and advanced therapeutic options.
• Novel agents like calcium sensitizers and PDE5 inhibitors show promise in managing critically ill patients with PH and RVF.
• Multidisciplinary approaches utilizing advanced diagnostics and targeted therapies are crucial for optimizing outcomes in ICU patients with pulmonary hypertension.